EGE. J. Gudgin

E. J. Gudgin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E. J. Gudgin has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • EntonoxTM as a sedative for bone marrow aspiration and biopsy

    by E. J. Gudgin, M. W. Besser, J. I. O. Craig

    Summary: Bone marrow aspiration and biopsy can be a painful procedure. Sedation techniques may make this investigation more acceptable to patients, but have the potential to cause life‐threatening complications, as well as requiring additional staff and equipment for safe administration. We assessed the use of EntonoxTM, a 50 : 50 mix of nitrous oxide and oxygen, as a sedation and analgesic agent, and compared it to previous experience with the intravenous (i.v.) benzodiazepine midazolam. Patients’ perception of pain, and both the operator and patient's views on the ease of the procedure and safety factors were recorded. Twenty‐two patients who had previously required i.v. midazolam sedation (16), or who requested sedation (6) were studied. Fifteen of 16 (94%) found EntonoxTM better or equal to midazolam, and only one patient (6%) found it worse. There were no serious adverse events due to EntonoxTM. We have shown, in this small group of patients, that EntonoxTM is an effective, safe alternative to intravenous midazolam for sedation during bone marrow biopsy, and is considered acceptable by both patients and staff. It has the major advantage that no additional staff or facilities are required for safe administration or monitoring the patient during or after the procedure.


  • Primary and isolated anaplastic large cell lymphoma of the bone marrow

    by E Gudgin, J Rashbass, Kj Pulford, Wn Erber

    Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma in which the majority of patients present with advanced stage III or IV disease. Here we report a case of ALCL where bone marrow was the only site of disease, in a 60-year-old man with pyrexia and pancytopenia. The diagnosis of ALCL was made on detection of CD30-positive anaplastic cells in the bone marrow, together with prominent hemophagocytosis. Genetics confirmed the clonal nature of the disease and showed it to be anaplastic lymphoma kinase (ALK) negative. Primary isolated bone marrow ALCL should be considered in the diagnosis of pancytopenia associated with hemophagocytosis.